A Lancet review finds modest yet meaningful slowing with lecanemab and donanemab, highlighting plasma p-tau217 as a scalable triage marker. While ARIA risk, eligibility limits, and payer decisions will determine the real-world impact, these findings ... [7864 chars].. reed more
